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Interventions to Improve Diabetes
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Review and Meta-Analysis
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1Unit of PharmacoTherapy, -Epidemiology and -Economics, Groningen Research Institute of Pharmacy, University of
Groningen, Groningen, Netherlands, 2 Pharmaceutical Care, NIVEL, Netherlands Institute for Health Services Research,
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Background: Treatment of diabetes requires a strict treatment scheme which
demands patient self-management. Pharmacists are in a good position to provide
self-management support. This review examines whether pharmacist-led interventions
to support self-management in diabetes patients improve clinical and patient-reported
outcomes.
Methods: This review was conducted according to the PRISMA guidelines. An
extended literature search was conducted with the keywords “pharmacist,” “diabetes,”
and “self-management” using the electronic databases Pubmed, Embase, CINAHL,
PsycINFO,Web of Science, and the Cochrane Library from the beginning of the database
through September 2017. In addition reference lists of systematic reviews and included
studies were searched. Eligibility criteria included; self-management intervention tested
with an RCT, performed in an ambulatory care setting, led by a pharmacist and reporting
at least one clinical- or patient-reported outcome. Primary outcomes were HbA1c (—as
this is a clinical parameter for long-term diabetes follow-up), self-management and
components of intervention. Secondary outcomes were blood glucose, blood pressure,
BMI, lipids, adherence to medication, quality of life, and diabetes knowledge. For the
meta-analysis HbA1c values were pooled with a random-effects model in Revman 5.3.
Risk of bias was assessed with the Cochrane Risk of Bias tool.
Results: Twenty-four studies representing 3,610 patients were included.
Pharmacist-led self-management interventions included education on diabetes
complications, medication, lifestyle, and teaching of self-management skills.
Some studies focused on patient needs through a tailored intervention. No key
components for a successful self-management intervention could be identified.
Pharmacist-led self-management interventions improve HbA1c levels with a mean
of 0.71% (CI −0.91, −0.51; overall effect P < 0.0001) and had a positive effect
on blood pressure (SBP −5.20mm Hg [−7.58; −2.92], DBP −3.51 mmHg
[−6.00; −1.01]), BMI (−0.49 kg/m² [−0.79; −0.19]), lipids (total cholesterol −0.19
mmol/l [−0.33; −0.05], LDL-C mmol/l −0.16 [−0.26; −0.06], HDL-C 0.32 mmol/l
[0.02; 0.61]), self-management skill development, and adherence to medication.
van Eikenhorst et al. Self-management Interventions in DM Patients
Conclusion: Pharmacist-led self-management interventions significantly improve
HbA1c values in diabetes patients. These results underline the added value of
pharmacists in patient-related care. Pharmacists should offer self-management support
to diabetes patients in order to improve diabetes outcomes.
Keywords: diabetes, pharmacist, pharmacy practice, self-management, HbA1c, meta-analysis
INTRODUCTION
Diabetes is a disease which is complex to manage. Treatment
consists of lifestyle adaptations often combined with medication
to control blood glucose levels (World Health Organization,
2016). Despite available treatment, diabetes is often associated
with complications and co-morbidities which increases the
complexity of disease management even further (Struijs et al.,
2006; Luijks et al., 2012; Lin et al., 2015). Self-management
is an essential part of diabetes disease management and
is mainly the patient’s responsibility. Self-management of
chronic conditions has been defined as: “The individual’s
ability to manage the symptoms, treatment, physical, and
psychosocial consequences and life style changes inherent in
living with a chronic condition. Efficacious self-management
encompasses the ability to monitor one’s condition and to
effect the cognitive, behavioral, and emotional responses
necessary to maintain a satisfactory quality of life.” (Barlow,
2001; Barlow et al., 2002) Patients—especially those with
complex diseases—often need support in developing and
maintaining self-management skills (Bodenheimer et al.,
2002).
Self-management interventions led by physicians, nurses,
dieticians, and diabetes educators have been shown to improve
HbA1c values in diabetes patients (Newman et al., 2004; Sherifali
et al., 2015). Over the years, several reviews have shown that
pharmacists also contribute additional value in diabetes care
for patients (Machado et al., 2007; Capoccia et al., 2016;
Greer et al., 2016; Pousinho et al., 2016). Although, these
reviews either studied any type of pharmacist intervention
instead of only self-care related interventions (Machado et al.,
2007; Greer et al., 2016; Pousinho et al., 2016) or merely
focused on adherence (Capoccia et al., 2016). For the U.S.,
meta-analyses for HbA1c changes were presented by Greer
et al. (2016). Machado et al. (2007) presented these figures
for studies conducted worldwide. But both studies did not
focus on the interventions to improve self-management skills.
Furthermore, the meta-analyses either were limited in their
scope to only the U.S. or are rather outdated. A comprehensive
updated review is needed to summarize the current evidence
on the role of pharmacists in supporting self-management
skills in diabetes patients. This is all the more important
because of the still ongoing paradigm shift of the role of the
pharmacist from being a drug supplier to a drug therapymanager
(Hepler and Strand, 1990; Wiedenmayer et al., 2006). The
aim of this systematic review is to examine the effectiveness
of pharmacist-led interventions to support self-management
in order to improve clinical- and patient-reported diabetes
outcomes.
METHODS
This review was reported according to the PRISMA statement
(Moher et al., 2009). The protocol was registered in the
Prospero International Prospective Register of Systematic
Reviews (registration number: CRD42016041859).
Research Question
This review assessed the effect of pharmacist-led
self-management interventions for diabetes patients on
clinical- and patient reported outcomes in randomized
controlled trials. Primary outcomes were HbA1c, self-
management skills, and intervention components. Secondary
outcomes were blood glucose, blood pressure, BMI, lipids,
adherence to medication, quality of life, and diabetes knowledge.
Data Sources and Searches
Pubmed, Embase, Cinahl, PsycINFO, Web of Science, and the
Cochrane Library were searched from the start date of the
database through to September 2017. Keywords used included
“pharmacist,” “diabetes,” and “self-management” (Supplementary
Table 1). Whenever possible MeSH terms and advanced searched
strategies were used (Supplementary Figure 1). The electronic
database searches were complemented bymanually reviewing the
references of relevant reviews and included studies.
Study Selection
Inclusion Criteria
A study was included in the review if; (1) the study population
was diagnosed with diabetes excluding gestational diabetes, (2)
the intervention targeted patients’ self-management (Barlow,
2001; Barlow et al., 2002) in an ambulatory care setting, (3) the
pharmacist, or a member of the pharmacy team, was involved in
the intervention, (4) data on one ormore outcomemeasures were
reported e.g., HbA1c, diabetes self-care activities, adherence,
(5) the study design was a randomized controlled trial, (6)
the full text article was published in either English or Dutch,
and (7) it was an original study published in a peer-reviewed
journal.
Self-management interventions are not always described
as such. Therefore, both direct and indirect self-management
interventions were included. By indirect self-management
interventions we mean interventions containing components
that eventually could lead to improved self-management skills,
e.g., diabetes and lifestyle education or concordant goal setting.
Study Selection
Two reviewers, LvE and LvD, independently assessed all titles
and abstracts identified with the initial searches. For all
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potentially eligible studies the full text papers were obtained
via the University of Groningen catalogs, open sources and
by emailing first authors. Full text papers were read by both
reviewers (LvE and LvD) independently for final inclusion. Any
disagreements between the reviewers were resolved by discussion
or consultation with a third party (HdG or KT).
Data Extraction and Quality Assessment
The following data were extracted from the included studies:
general study characteristics, description of the study population,
follow-up time, number and duration of contact moments
during intervention, description, and components of the
intervention [diabetes education, medication, lifestyle,
individual care plan or goal setting, self-management skills,
self-monitoring blood glucose (SMBG) and other, group or
individual intervention, education for intervention team],
clinical outcomes (HbA1c, blood glucose, blood pressure,
BMI, lipid profile, and other), and patient-reported outcomes
(adherence, diabetes knowledge, quality of life, self-care/self-
management, and other) (Supplementary Table 2). Also it
was noted whether interventions were tailored according
to the patient’s needs. A study was categorized as being
tailored if the author made this statement in the research
paper. The review team did not base the classification of
tailoring on literature statements (Kreuter and Wray, 2003;
Noar et al., 2007). The study data were extracted by LvE
and double checked for eight papers by LvD, KT, and HdG.
Any disagreements were discussed until consensus was
reached.
The risk of bias in individual studies was assessed with the
Cochrane Risk of Bias tool by LvE (Higgins and Green, 2011).
This assessment was double checked by LvD, KT, and HdG by
assessing the risk of bias in eight studies. Any disagreements were
discussed until consensus was reached.
Data Synthesis and Analysis
Interventions across the included studies were analyzed and
described narratively.
Outcomes were divided into clinical outcomes (HbA1c,
glucose levels, blood pressure, BMI, lipids, and other) and
patient-reported outcomes (adherence, diabetes knowledge,
quality of life, self-care, and other). Results for HbA1c, blood
glucose, blood pressure, BMI, lipids, and Summary of Diabetes
Self-care Activities Assessment (SDSCA) were pooled in a meta-
analysis.Meta-analyses were performedwith ReviewManager 5.3
by using a random effects model because of clinical heterogeneity
across the included studies. Subgroup analyses were performed
for the outcome HbA1c, for different intervention elements
(follow-up time, baseline HbA1c ≤ 7% and education for
intervention team) in order to explain any heterogeneity (I²)
across the studies and to explore key intervention components.
Sensitivity analyses were performed to test for robustness of the
results regarding including studies with a cluster randomization
design and studies with a high risk of bias affecting the outcome
HbA1c. Results for adherence, diabetes knowledge and quality of
life were described narratively.
RESULTS
In total 5,919 hits were identified from the electronic database
searches, of which 3,996 were unique. After the title and abstract
assessment 3,932 references were excluded because they did
not meet the inclusion criteria. The full text of 64 papers was
assessed, with 24 papers finally being included in the review.
(Figure 1, Supplementary Table 3 for extended data extraction
information). Reasons for exclusion after full-text assessment are
presented in Supplementary Table 4. Study characteristics of the
included studies are presented in Table 1 and characteristics of
the study populations of the included studies are presented in
Table 2.
Description of Included Studies
Three of the included studies had a cluster randomized design
(Armour et al., 2004; Krass et al., 2007; Mehuys et al., 2011) and
21 were randomized controlled trials (Sarkadi and Rosenqvist,
2004; Choe et al., 2005; Odegard et al., 2005; Doucette et al., 2009;
Jameson and Baty, 2010; Taveira et al., 2010, 2011; Cohen et al.,
2011; Farsaei et al., 2011; Jacobs et al., 2012; Jarab et al., 2012;
FIGURE 1 | Flow chart study selection.
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TABLE 2 | Main characteristics of the study populations.











IG 53 45 64 ± 9 7.9 ± 1.5 NR 2 Heart disease, hypertension,
hyperlipidemiaCG 46 51 65 ± 10 7.4 ± 1.2 NR
Butt et al., 2015 IG 33 39.4 57.4 ± 7.2 9.66 ± 1.57 62.5 2 NR
CG 33 42.4 57.1 ± 10.8 9.64 ± 1.41 46.3
Cani et al., 2015 IG 34 38.2 61.9 ± 9.6 9.78 ± 1.55 100 2 NR
CG 36 38.9 61.6 ± 8.1 9.61 ± 1.38 100
Choe et al., 2005 IG 41 48.8 52.2 ± 11.2 10.1 ± 1.8 29.3 2 NR
CG 39 46.1 51.0 ± 9.0 10.2 ± 1.7 30.8
Cohen et al., 2011 IG 50 100 69.8 ± 10.7 7.8 ± 1.0 NR 2 Heart failure, stroke,
coronary heart disease,
COPD, mood disorder
CG 49 96 67.2 ± 9.4 8.1 ± 1.4 NR
Doucette et al.,
2009
IG 31 41.7 58.7 ± 13.3 7.99 ± 1.45 NR 2 NR
CG 35 47.6 61.2 ± 10.9 7.91 ± 1.91 NR
Farsaei et al., 2011 IG 87 36.8 53.4 ± 9.8 9.3 ± 1.7 13.1 2 Hypertension, dyslipidemia,
heart disease, thyroid
disease, renal disease
CG 87 31.8 52.9 ± 8.5 8.9 ± 1.1 11.5
Jacobs et al.,
2012
IG 72 68 62.7 ± 10.8 9.5 ± 1.1 19 2 Retinopathy, nephropathy,




IG 45 51 57.3 ± 8.6 7.6 ± 1.6 NR 2 NR
CG 40 48 55.9 ± 8.7 7.51 ± 1.8 NR
Jameson and
Baty, 2010
IG 52 48.9 49.3 ± 10.8 10.4 ± 1.2 23 NR NR
CG 51 49 49.7 ± 10.9 11.1 ± 1.6 28
Jarab et al., 2012 IG 77 57.6 63.4 ± 10.1 8.5 65.9 2 NR
CG 79 55.8 65.3 ± 9.2 8.4 69.8
Kjeldsen et al.,
2015
IG-B 33 57.9 63 ± 8.8 NR NR 2 NR
IG-E 37 59.5 63.4 ± 7.8 NR NR
CG 102 62.4 62.1 ± 10.2 NR NR
Korcegez et al.,
2017





CG 77 26.0 62.2 ± 9.54 8.31 ± 0.84 51.9
Kraemer et al.,
2012
IG 36 61.1 55.6 ± 6.8 7.28 13.9 1 & 2 NR
CG 29 38.7 52.6 ± 9.2 7.38 32.3
Krass et al., 2007 IG 125 51 62 ± 11 8.9 ± 1.4 NR 2 Hypertension, hyperlipidemia
CG 107 51 62 ± 11 8.3 ± 1.3 NR
Mehuys et al.,
2011
IG 153 51.0 63 7.7 6.8 2 NR
CG 135 53.7 62.3 7.3 11.4
Nascimento et al.,
2015
IG 44 56.8 74.2 ± 5.4 8.6 ± 1.2 27.3 2 Hypertension, dyslipidemia,
vascular complicationsCG 43 58.1 72.3 ± 4.5 8.2 ± 0.7 34.9
Odegard et al.,
2005
IG 39 52 51.6 ± 11.6 10.2 ± 0.8 26 2 NR
CG 27 64 51.9 ± 10.4 10.6 ± 1.4 38
Samtia et al., 2013 IG 108 52.8 46.1 8.51 8.3 2 NR
CG 97 48.2 42.3 8.54 14.1
Sarkadi and
Rosenqvist, 2004
IG 33 NR 66.4 6.45 NR 2 NR
CG 31 NR 66.5 6.45 NR
Shao et al., 2017 IG 99 51.0 58.7 ± 10.59 7.38 ± 1.71 NR 2 NR
CG 100 47.5 59.2 ± 10.34 7.37 ± 1.44 NR
Taveira et al., 2010 IG 58 91.4 62.2 ± 10.3 8.5 ± 1.5 NR 2 Hypertension,
hyperlipidemia, coronary
artery disease, congestive
heart failure, COPDCG 51 100 66.8 ± 10.2 7.9 ± 1.1 NR
(Continued)
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TABLE 2 | Continued









Taveira et al., 2011 IG 44 100 60.2 ± 9.3 8.3 ± 1.7 NR 2 Depression, coronary artery
disease, anxiety,
schizophrenia, bipolar, PTSDCG 44 95.5 61.4 ± 9.9 8.5 ± 1.9 NR
Wishah et al.,
2015
IG 52 38.5 52.9 ± 9.6 8.9 ± 1.6 NR 2 NR
CG 54 48.1 53.2 ± 11.2 8.2 ± 1.3 NR
CG, control group; IG, intervention group; IG-B, basic intervention group; IG-E, extended intervention group.
Kraemer et al., 2012; Samtia et al., 2013; Butt et al., 2015; Cani
et al., 2015; Jahangard-Rafsanjani et al., 2015; Kjeldsen et al., 2015;
Nascimento et al., 2015; Wishah et al., 2015; Korcegez et al., 2017;
Shao et al., 2017) (Table 1). All studies were published from 2004
onwards. Most of the studies were conducted in North America
(Choe et al., 2005; Odegard et al., 2005; Doucette et al., 2009;
Jameson and Baty, 2010; Taveira et al., 2010, 2011; Cohen et al.,
2011; Jacobs et al., 2012; Kraemer et al., 2012) (9), followed by
Asia (Farsaei et al., 2011; Jarab et al., 2012; Samtia et al., 2013;
Butt et al., 2015; Jahangard-Rafsanjani et al., 2015; Wishah et al.,
2015; Shao et al., 2017) (7), Europe (Sarkadi and Rosenqvist,
2004; Mehuys et al., 2011; Kjeldsen et al., 2015; Nascimento et al.,
2015; Korcegez et al., 2017) (5), Australia (Armour et al., 2004;
Krass et al., 2007) (2), and South America (Cani et al., 2015) (1).
Themajority of the studies focused primarily on diabetes mellitus
type 2 patients (Armour et al., 2004; Sarkadi and Rosenqvist,
2004; Choe et al., 2005; Odegard et al., 2005; Krass et al., 2007;
Doucette et al., 2009; Taveira et al., 2010, 2011; Cohen et al.,
2011; Farsaei et al., 2011; Mehuys et al., 2011; Jacobs et al., 2012;
Jarab et al., 2012; Samtia et al., 2013; Butt et al., 2015; Cani
et al., 2015; Jahangard-Rafsanjani et al., 2015; Kjeldsen et al., 2015;
Nascimento et al., 2015; Wishah et al., 2015; Korcegez et al., 2017;
Shao et al., 2017) (22), one study included both type 1 and type 2
patients (Kraemer et al., 2012) and one study did not specify the
type of diabetes (Jameson and Baty, 2010). In total the included
studies represented 3,610 participants with a mean age ranging
from 44 to 73 years of age. The median follow-up time was 6
months (Krass et al., 2007; Cohen et al., 2011; Mehuys et al., 2011;
Taveira et al., 2011; Jarab et al., 2012; Butt et al., 2015; Cani et al.,
2015; Kjeldsen et al., 2015; Nascimento et al., 2015; Wishah et al.,
2015; Korcegez et al., 2017), four studies had a follow-up time of
less than 6months (Taveira et al., 2010; Farsaei et al., 2011; Samtia
et al., 2013; Jahangard-Rafsanjani et al., 2015) and 10 of more
than 6 months (Armour et al., 2004; Sarkadi and Rosenqvist,
2004; Choe et al., 2005; Odegard et al., 2005; Doucette et al., 2009;
Jameson and Baty, 2010; Jacobs et al., 2012; Kraemer et al., 2012;
Shao et al., 2017).
Description of Intervention
The interventions in the included studies were all provided by
a trained pharmacist, either by the pharmacist alone (Armour
et al., 2004; Choe et al., 2005; Odegard et al., 2005; Krass
et al., 2007; Doucette et al., 2009; Jameson and Baty, 2010;
Farsaei et al., 2011; Mehuys et al., 2011; Jacobs et al., 2012;
Jarab et al., 2012; Kraemer et al., 2012; Samtia et al., 2013;
Butt et al., 2015; Cani et al., 2015; Jahangard-Rafsanjani et al.,
2015; Kjeldsen et al., 2015; Wishah et al., 2015; Korcegez et al.,
2017; Shao et al., 2017) or within a multi-disciplinary team
(Sarkadi and Rosenqvist, 2004; Taveira et al., 2010, 2011; Cohen
et al., 2011). One study did not specify the intervention team,
besides including a pharmacist (Nascimento et al., 2015). Most
interventions targeted the individual patient (Armour et al., 2004;
Choe et al., 2005; Odegard et al., 2005; Krass et al., 2007; Doucette
et al., 2009; Jameson and Baty, 2010; Mehuys et al., 2011; Jacobs
et al., 2012; Jarab et al., 2012; Kraemer et al., 2012; Samtia et al.,
2013; Butt et al., 2015; Cani et al., 2015; Jahangard-Rafsanjani
et al., 2015; Kjeldsen et al., 2015; Wishah et al., 2015; Korcegez
et al., 2017; Shao et al., 2017) whereas some interventions used
group sessions (Sarkadi and Rosenqvist, 2004; Taveira et al., 2010,
2011; Cohen et al., 2011). One study did not specify whether
the intervention was offered in an individual or group setting
(Farsaei et al., 2011). Fifteen studies reported offering a tailored
intervention based on a patient’s specific needs (Armour et al.,
2004; Odegard et al., 2005; Krass et al., 2007; Jameson and Baty,
2010; Taveira et al., 2010, 2011; Farsaei et al., 2011; Jarab et al.,
2012; Kraemer et al., 2012; Cani et al., 2015; Jahangard-Rafsanjani
et al., 2015; Kjeldsen et al., 2015; Nascimento et al., 2015; Wishah
et al., 2015; Korcegez et al., 2017).
The interventions in the included studies varied in the
intensity as well as the number and type of components.
The intensity, measured as the frequency of contact moments,
differed across the studies from once a week to once every
3 months. Face-to-face contact with the pharmacists (Armour
et al., 2004; Sarkadi and Rosenqvist, 2004; Krass et al., 2007;
Doucette et al., 2009; Taveira et al., 2010, 2011; Cohen et al.,
2011; Mehuys et al., 2011; Jacobs et al., 2012; Kraemer et al., 2012;
Samtia et al., 2013; Butt et al., 2015; Cani et al., 2015; Jahangard-
Rafsanjani et al., 2015; Kjeldsen et al., 2015; Nascimento et al.,
2015; Wishah et al., 2015; Korcegez et al., 2017) (18) as well
as a combination of face-to-face contacts and telephone contact
with the pharmacists (Choe et al., 2005; Odegard et al., 2005;
Jameson and Baty, 2010; Farsaei et al., 2011; Jarab et al., 2012;
Shao et al., 2017) (6) were reported in the studies. The total
contact time varied across the studies, though not all studies
reported this information (Armour et al., 2004; Sarkadi and
Rosenqvist, 2004; Doucette et al., 2009; Farsaei et al., 2011;
Mehuys et al., 2011; Taveira et al., 2011; Jacobs et al., 2012;
Samtia et al., 2013; Cani et al., 2015; Nascimento et al., 2015;
Korcegez et al., 2017; Shao et al., 2017). (Table 1). Fifteen studies
included diabetes education (Sarkadi and Rosenqvist, 2004; Krass
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et al., 2007; Taveira et al., 2010, 2011; Cohen et al., 2011; Mehuys
et al., 2011; Jacobs et al., 2012; Jarab et al., 2012; Samtia et al.,
2013; Butt et al., 2015; Cani et al., 2015; Jahangard-Rafsanjani
et al., 2015; Wishah et al., 2015; Korcegez et al., 2017; Shao
et al., 2017) either about diabetes in general or about acute and
chronic complications. Education on medication was provided
in 21 studies (Armour et al., 2004; Sarkadi and Rosenqvist,
2004; Choe et al., 2005; Odegard et al., 2005; Krass et al., 2007;
Doucette et al., 2009; Jameson and Baty, 2010; Cohen et al., 2011;
Farsaei et al., 2011; Mehuys et al., 2011; Taveira et al., 2011;
Jacobs et al., 2012; Jarab et al., 2012; Samtia et al., 2013; Butt
et al., 2015; Cani et al., 2015; Kjeldsen et al., 2015; Nascimento
et al., 2015; Wishah et al., 2015; Korcegez et al., 2017; Shao
et al., 2017) and included education about adherence, dosage,
drug-related problems, indication, storage, and use. In 19 studies
education on lifestyle, including diet, exercise, foot care, and/or
smoking cessation were part of the intervention (Armour et al.,
2004; Sarkadi and Rosenqvist, 2004; Odegard et al., 2005; Krass
et al., 2007; Jameson and Baty, 2010; Taveira et al., 2010, 2011;
Cohen et al., 2011; Farsaei et al., 2011; Mehuys et al., 2011;
Jacobs et al., 2012; Jarab et al., 2012; Samtia et al., 2013; Butt
et al., 2015; Cani et al., 2015; Jahangard-Rafsanjani et al., 2015;
Wishah et al., 2015; Korcegez et al., 2017; Shao et al., 2017).
In 19 studies the intervention included self-management skills
support (Armour et al., 2004; Sarkadi and Rosenqvist, 2004; Choe
et al., 2005; Odegard et al., 2005; Krass et al., 2007; Doucette
et al., 2009; Jameson and Baty, 2010; Taveira et al., 2010, 2011;
Cohen et al., 2011; Farsaei et al., 2011; Jacobs et al., 2012; Kraemer
et al., 2012; Samtia et al., 2013; Jahangard-Rafsanjani et al., 2015;
Nascimento et al., 2015; Wishah et al., 2015; Korcegez et al., 2017;
Shao et al., 2017) and in 15 studies participants were trained
in self-monitoring blood glucose (Armour et al., 2004; Sarkadi
and Rosenqvist, 2004; Odegard et al., 2005; Krass et al., 2007;
Jameson and Baty, 2010; Cohen et al., 2011; Taveira et al., 2011;
Jarab et al., 2012; Kraemer et al., 2012; Samtia et al., 2013; Butt
et al., 2015; Cani et al., 2015; Jahangard-Rafsanjani et al., 2015;
Korcegez et al., 2017; Shao et al., 2017). A total of 14 studies
used either an individual care plan or goal setting to improve
diabetes outcomes (Armour et al., 2004; Odegard et al., 2005;
Krass et al., 2007; Doucette et al., 2009; Taveira et al., 2010, 2011;
Cohen et al., 2011; Farsaei et al., 2011; Jacobs et al., 2012; Kraemer
et al., 2012; Jahangard-Rafsanjani et al., 2015; Kjeldsen et al., 2015;
Wishah et al., 2015; Korcegez et al., 2017). Other less common
interventions were the use of a diabetes diary (Farsaei et al., 2011;
Butt et al., 2015; Jahangard-Rafsanjani et al., 2015), medication
reviews by a pharmacist (Armour et al., 2004; Choe et al., 2005;
Krass et al., 2007; Doucette et al., 2009; Jacobs et al., 2012;
Korcegez et al., 2017), and providing participants with written
information (Sarkadi and Rosenqvist, 2004; Jarab et al., 2012;
Cani et al., 2015; Jahangard-Rafsanjani et al., 2015; Nascimento
et al., 2015; Wishah et al., 2015; Korcegez et al., 2017).
Many different outcome measures were reported by the
included studies (Table 1). They were divided in clinical and
patient-reported outcomes.
Clinical Outcomes
All studies reported HbA1c as an outcome measurement for
their intervention. A meta-analysis was performed, with one
study excluded because of an insufficient number of participants
reporting HbA1c at the final follow-up (Kjeldsen et al., 2015).
The meta-analysis (Figure 2) shows an overall significant
effect in favor of the intervention on HbA1c, with HbA1c levels
improving by a mean of 0.71% (CI −0.91, −0.51; overall effect P
< 0.0001). Several subgroup analyses were performed based on
different study characteristics (Table 3, Supplementary Figures
2A–I). None of these subgroup analyses showed a significant
difference between groups.
Other clinical outcomes reported were blood glucose levels,
blood pressure, BMI, and lipid profile (Table 4, Supplementary
Figures 3–6). Meta-analyses showed no significant reduction for
blood glucose levels, but a significant improvement in systolic-
and diastolic blood pressure (−5.20mm Hg [−7.58; −2.92] and
−3.51mm Hg [−6.00; −1.01], respectively), BMI scores (−0.49
kg/m² [−0.79; −0.19]), total cholesterol levels (−0.19 mmol/l
[−0.33; −0.05]), LDL-C levels (−0.16 mmol/l [−0.26; −0.06]),
and HDL-C levels (0.32 mmol/l [0.02; 0.61]).
Patient Reported Outcomes
Self-management
Adherence to diabetes self-care was assessed in 12 studies
(Doucette et al., 2009; Taveira et al., 2010, 2011; Cohen et al.,
2011; Mehuys et al., 2011; Jarab et al., 2012; Kraemer et al.,
2012; Jahangard-Rafsanjani et al., 2015; Kjeldsen et al., 2015;
Nascimento et al., 2015; Wishah et al., 2015; Korcegez et al.,
2017). Nine of them used the validated Summary of Diabetes Self-
Care Activities assessment (SDSCA) (Doucette et al., 2009; Cohen
et al., 2011; Mehuys et al., 2011; Taveira et al., 2011; Jarab et al.,
2012; Jahangard-Rafsanjani et al., 2015; Nascimento et al., 2015;
Wishah et al., 2015; Korcegez et al., 2017). This questionnaire
consists of five domains (general diet, specific diet, exercise,
self-monitoring blood glucose, foot care), and domain scores as
well as an overall score can be calculated. Six studies reported
domain scores (Cohen et al., 2011; Mehuys et al., 2011; Jarab
et al., 2012; Jahangard-Rafsanjani et al., 2015; Nascimento et al.,
2015; Wishah et al., 2015). The results of these six studies were
pooled in a meta-analysis and a significant effect of pharmacist-
led interventions was found for general diet, self-monitoring
blood glucose, foot care, and exercise (Figures 3A–F).
Adherence to Medication
Adherence to medication was measured in 13 studies (Odegard
et al., 2005; Mehuys et al., 2011; Jarab et al., 2012; Kraemer
et al., 2012; Samtia et al., 2013; Butt et al., 2015; Cani et al.,
2015; Jahangard-Rafsanjani et al., 2015; Kjeldsen et al., 2015;
Nascimento et al., 2015; Wishah et al., 2015; Korcegez et al.,
2017; Shao et al., 2017). Seven studies (Jarab et al., 2012; Butt
et al., 2015; Cani et al., 2015; Jahangard-Rafsanjani et al., 2015;
Wishah et al., 2015; Korcegez et al., 2017; Shao et al., 2017)
used the validatedMorisky-Green questionnaire. Due to different
reporting strategies it was not possible to pool the results. Six
studies reported significant improvement in adherence in the
intervention group compared to the control group and one study
reported improved adherence outcomes within the intervention
group but did not compare intervention and control group
(Korcegez et al., 2017).
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FIGURE 2 | Meta-analysis HbA1c.
Quality of Life
Six studies (Armour et al., 2004; Krass et al., 2007; Cohen
et al., 2011; Butt et al., 2015; Cani et al., 2015; Kjeldsen et al.,
2015) reported quality of life outcomes, of which three studies
(Krass et al., 2007; Butt et al., 2015; Kjeldsen et al., 2015)
used the validated EQ-5D(-3L) questionnaire. Due to the use
of different versions of the questionnaire and differences in
reporting strategies it was not possible to pool the results. Two
studies reported significantly improved quality of life based on
the results from the EQ-5D tool (Krass et al., 2007; Butt et al.,
2015).
Diabetes Knowledge
Diabetes knowledge was reported in six studies (Mehuys et al.,
2011; Kraemer et al., 2012; Samtia et al., 2013; Butt et al.,
2015; Kjeldsen et al., 2015; Wishah et al., 2015), of which three
studies (Mehuys et al., 2011; Kraemer et al., 2012; Wishah
et al., 2015) used the validated Diabetes Knowledge Test of
The Michigan Diabetes Research and Training Center. Due to
the use of different reporting strategies it was not possible to
pool the results. Only Wishah et al. (2015) reported significant
improvement of diabetes knowledge.
Risk of Bias
The risk of bias within studies was assessed with the Cochrane
Risk of Bias tool. All but two (Taveira et al., 2011; Jarab et al.,
2012) studies were subjected to some form of bias either at
high risk or at an unclear risk due to lack of information
(Supplementary Figure 7). In total, eight studies were considered
to have a low risk of bias (Sarkadi and Rosenqvist, 2004; Jameson
and Baty, 2010; Taveira et al., 2011; Jacobs et al., 2012; Jarab et al.,
2012; Butt et al., 2015; Cani et al., 2015; Wishah et al., 2015).
Publication Bias
The funnel plot for the pooled results of HbA1c can be considered
symmetric and indicates that it is unlikely publication bias has
been introduced in the analysis (Supplementary Figure 8).
Sensitivity Analysis
Two sensitivity analyses were performed. In the first sensitivity
analysis the studies with a cluster randomization design were
excluded, because none of these studies corrected for the
clustering effect. The clustering effect is known for potential
overestimation of the effect of the intervention (Killip et al.,
2004). After excluding these studies the weightedmean difference
of HbA1c for the patient-level randomized studies was −0.76%
[−1.00; −0.52]. This difference is of the same magnitude as the
difference observed when including all studies.
The second sensitivity analysis was performed using only the
eight studies with a relatively low risk of bias from influences on
HbA1c. The weighted mean difference of HbA1c for studies with
a low risk of bias was −0.84% [−1.11; −0.57]. This difference
is also of the same magnitude as the difference observed when
including all studies.
DISCUSSION
Summary of Main Findings
This review found evidence that pharmacist-led self-
management interventions are beneficial for diabetes patients.
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TABLE 3 | Subgroup analyses HbA1c.
Subgroup N I² (P-value) CI Test for subgroup differences
1 Overall 23 61% (P < 0.0001) −0.71 [−0.91; −0.51] –
2.1 Tailored intervention P = 0.33, I² = 0%
2.1.1 Yes 13 72% (P < 0.0001) −0.79 [−1.14; −0.44]
2.1.2 No 10 0% (P = 0.58) −0.60 [−0.76; −0.44]
3.1 Group vs. individual intervention P = 0.53; I² = 0%
3.1.1 Group 4 23% (P = 0.27) −0.61 [−0.92; −0.30]
3.1.2 Individual 19 65% (P < 0.0001) −0.73 [−0.97; −0.50]
4.1 Follow-up time P = 0.57; I² = 0%
4.1.1 <6 months 4 84% (P = 0.0002) −0.98 [−1.68; −0.28]
4.1.2 6 months 10 0% (P = 0.55) −0.62 [−0.80; −0.44]
4.1.3 >6 months 9 17% (P = 0.29) −0.58 [−0.79; −0.37]
5.1 Follow-up time P = 0.30; I² = 5.0%
5.1.1 <6 months 4 84% (P = 0.0002) −0.98 [−1.68; −0.28]
5.1.2 ≥6 months 19 0% (P = 0.48) −0.60 [−0.73; −0.48]
6.1 HbA1c baseline cut off 7% P = 0.21; I² = 37.7%
6.1.1 <7% 2 0% (P = 0.45) −0.49 [−0.82; −0.15]
6.1.2 >7% 21 62% (P < 0.0001) −0.74[−0.96; −0.52]
7.1 Education intervention team P = 0.05; I² = 75%
7.1.1 Yes 7 0% (P = 0.90) −0.51 [−0.68; −0.34]
7.1.2 No 16 64% (P = 0.0003) −0.85 [−1.14; −0.56]
8.1 Adherence P = 0.35; I² = 0%
8.1.1 Yes 12 76% (P < 0.00001) −0.77 [−1.09; −0.46]
8.1.2 No 11 0% (P = 0.63) −0.60 [−0.79; −0.40]
9.1 DRP/side effects P = 0.26; I² = 20.1%
9.1.1 Yes 9 79% (P < 0.00001) −0.84 [−1.24; −0.41]
9.1.2 No 14 0% (P = 0.68) −0.57 [−0.73; −0.41]
10.1 Individual Care Plan/Goal setting P = 0.42; I² = 0%
10.1.1 Yes 11 77% (P < 0.00001) −0.76 [−1.11; −0.40]
10.1.2 No 12 0% (P = 0.67) −0.60 [−0.77; −0.42]
All of the included studies used proxies to measure the effect
of self-management interventions; only a minority directly
measured the effect of self-management interventions on
self-management skills. Overall, pharmacist-led interventions
had a positive effect on HbA1c values, blood pressure, BMI,
and self-management skills as shown by the results of the
meta-analyses. Also the results suggest pharmacist-led self-
management interventions improve adherence to medication,
diabetes knowledge, and quality of life.
The results on HbA1c values in the meta-analysis showed a
significant effect of pharmacist-led interventions. The magnitude
of this reduction (−0.71% [−0.91; −0.51]) can be considered
as clinically relevant and can be associated with risk reduction
in microvascular complications (Stratton et al., 2000). These
findings are in agreement with the findings of Machado et al.
(2007), who reported a pooled effect of −1.00 ± 0.28%
on HbA1c values. However, in their review all kinds of
pharmacist interventions for diabetes patients were included.
Compared to systematic reviews on the effect of self-management
interventions by either a physician, nurse or diabetes educator,
the effect of pharmacist-led self-management interventions was
over three times larger (Sherifali et al., 2015). The added value
of pharmacist-led interventions for diabetes goal attainment is
supported by the findings of Greer et al. (2016), who reported
a relative risk (1.83 [1.44; 2.33]) in favor of diabetes patients
receiving pharmacist-led disease management. The diversity of
intervention contents in the included studies is also highlighted
in previous reviews (Machado et al., 2007; Greer et al., 2016;
Pousinho et al., 2016).
Strengths and Limitations
This study has several strengths. All of the studies included
measured HbA1c values, which made it possible to compare
the effect of the described interventions in a meta-analysis. Also
the results for blood glucose, blood pressure, BMI, lipids, and
self-management skills could be pooled in meta-analyses.
Though most studies used proxies to measure the effect
of pharmacist-led self-management interventions, a few studies
directly measured self-management. The results of these studies
reveal a positive direct relation between the self-management
intervention and the development of self-management skills in
diabetes patients. This is most likely because the interventions
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TABLE 4 | Pooled outcomes clinical parameters.
Outcome Pooled results
(mean, CI)
Blood glucose (mmol/l) (Farsaei et al., 2011; Mehuys
et al., 2011; Jarab et al., 2012; Kraemer et al., 2012;
Samtia et al., 2013; Butt et al., 2015; Nascimento et al.,
2015; Wishah et al., 2015; Korcegez et al., 2017; Shao
et al., 2017)
−0.26 [−0.97; 0.46]
Blood pressure (mm Hg)
• Systolic blood pressure (Krass et al., 2007; Doucette
et al., 2009; Taveira et al., 2010, 2011; Cohen et al.,
2011; Jacobs et al., 2012; Jarab et al., 2012; Kraemer
et al., 2012; Jahangard-Rafsanjani et al., 2015;
Korcegez et al., 2017; Shao et al., 2017)
−5.20 [−7.48; −2.92]
• Diastolic blood pressure (Krass et al., 2007; Doucette
et al., 2009; Taveira et al., 2010; Jacobs et al., 2012;
Jarab et al., 2012; Kraemer et al., 2012;
Jahangard-Rafsanjani et al., 2015; Korcegez et al.,
2017; Shao et al., 2017)
−3.51 [−6.00; −1.01]
BMI (kg/m²) (Taveira et al., 2010; Jarab et al., 2012;
Samtia et al., 2013; Butt et al., 2015;
Jahangard-Rafsanjani et al., 2015; Wishah et al., 2015;
Korcegez et al., 2017; Shao et al., 2017)
−0.49 [−0.79; −0.19]
Lipids (mmol/l)
• Total cholesterol (Krass et al., 2007; Jarab et al., 2012;
Kraemer et al., 2012; Butt et al., 2015; Wishah et al.,
2015; Korcegez et al., 2017; Shao et al., 2017)
−0.19 [−0.33; −0.05]
• LDL-C (Doucette et al., 2009; Taveira et al., 2010,
2011; Cohen et al., 2011; Jacobs et al., 2012; Jarab
et al., 2012; Kraemer et al., 2012; Butt et al., 2015;
Wishah et al., 2015; Korcegez et al., 2017; Shao et al.,
2017)
−0.16 [−0.26; −0.06]
• HDL-C (Jarab et al., 2012; Kraemer et al., 2012; Butt
et al., 2015; Wishah et al., 2015; Korcegez et al.,
2017; Shao et al., 2017)
0.32 [0.02; 0.61]
• Triglycerides (Krass et al., 2007; Jarab et al., 2012;
Kraemer et al., 2012; Butt et al., 2015; Wishah et al.,
2015; Korcegez et al., 2017; Shao et al., 2017)
−0.01 [−0.06; 0.03]
in almost all of the included studies addressed medication and
medication-related problems that are rather common among
diabetes patients (Haugbolle andWesth Sorensen, 2006; Kempen
et al., 2014).
This study also has some limitations. The reporting of the
interventions and study results were very limited in some of the
studies (Armour et al., 2004; Choe et al., 2005; Odegard et al.,
2005; Krass et al., 2007; Doucette et al., 2009; Taveira et al.,
2010; Cohen et al., 2011; Farsaei et al., 2011; Mehuys et al., 2011;
Kraemer et al., 2012; Samtia et al., 2013; Jahangard-Rafsanjani
et al., 2015; Kjeldsen et al., 2015; Nascimento et al., 2015). This
made the risk of bias assessment difficult. However, the sensitivity
analysis showed that excluding studies with a high risk of bias
did not materially change the results of the meta-analysis of the
HbA1c values.
The most frequently used instrument to measure self-
management in diabetes patients was the SDSCA questionnaire.
However, the SDSCA questionnaire pays limited attention to
medication related issues (Toobert et al., 2000). Therefore,
this questionnaire may not be the best instrument to measure
the effects of pharmacist-led and medication-related self-
management support. A more suitable instruments for instance
might be the MUSE questionnaire (Medication Understanding
andUse Self-Efficacy Scale), which focuses onmedication use and
knowledge (Cameron et al., 2010). This scale can be used among
patients with any level of health literacy.
The interventions reported in all of the included studies can
be considered as complex interventions, because all of them
consisted ofmultiple components. Also themechanisms of action
for implicating practice were complex as this depended on both
the pharmacists delivering and implementing the intervention
and the patient implementing it into daily life (Kelly et al., 2017).
In this review we have shown that these complex interventions
have a positive influence on various diabetes related outcomes.
Subgroup analyses did not provide evidence which of the
components were essential for the effect. More sophisticated
analyses, such as meta-regression analyses or modeling, could
have given more insight into key components (Viswanathan
et al., 2017). However, this was not possible due to the limited
number of studies, data available and the different ways in
which the data was presented in the included studies. Although,
we have described the different components of pharmacist-
led self-management interventions, the ideal composition of
intervention components is still a black box.
Clinical Implications and Future Research
The overall results of our study argue that pharmacists take
an active role in improving patient diabetes self-management
since the effectiveness of pharmacist-led interventions is at least
comparable to that of other healthcare providers (Sherifali et al.,
2015). Although we were unable to identify specific factors
contributing to the success of pharmacist-led self-management
interventions, a tailored approach seems to be preferable for
future developments (Linn et al., 2011, 2013; Harrington and
Noar, 2012). In line with findings of previous studies; self-
management needs depend on personal characteristics and
development (Bos-Touwen et al., 2015) and self-management
support should focus on how to identify problems and how to
take appropriate actions (Bodenheimer et al., 2002). Another
important factor for successful interventions might be the
intensity of contact moments over time, with the intensity of
contact moments appearing more important than the length of
the intervention. This is demonstrated by Krass et al. (2011) and
Odegard et al. (2005) who found that prolonging the follow-up
time without sustaining the contact frequency did not further
improve HbA1c values. Moreover, some patient groups are more
vulnerable to having low self-management skills than others.
For example, patients with a low level of health literacy may
benefit much more from self-management support compared
to more health literate diabetes patients (Fransen et al., 2012,
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FIGURE 3 | Pooled results SDSCA categories.
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2015). Summarizing the evidence, pharmacists should offer self-
management support to diabetes patients in order to improve
clinical- and patient reported diabetes outcomes.
Future research into self-management support should
focus on developing an intervention from a multidisciplinary
perspective to combine the knowledge from the different
disciplines involved in diabetes care. Most studies only focus
on the role of a single healthcare professional. Combining
the strengths of different disciplines might increase the effect
of the intervention. Particular emphasis should be placed on
vulnerable patient groups and using valid measurements of
self-management skills in multiple dimensions.
CONCLUSION
This review demonstrates that pharmacists contribute additional
value in self-management support interventions for diabetes
patients. Pharmacists are involved in a variety of different self-
management interventions, which vary in many key aspects
such as follow-up time and use of a tailored approach. Overall
pharmacist-led self-management interventions have a positive
effect on lowering HbA1c values.
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